Vaccine News and Research

Latest Vaccine News and Research

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.

3 Mar 2010

FDA issues final guidance to help develop safe and effective cell-based viral vaccines

The U.S. Food and Drug Administration today issued final guidance to help manufacturers who are developing safe and effective cell-based viral vaccines to address emerging and pandemic threats.

3 Mar 2010

Unilife agrees to Exclusivity List; Sanofi-aventis secures exclusivity for Unifill syringe

Unilife Corporation, today announced that it has agreed to a list of therapeutic drug classes ("Exclusivity List") within which sanofi-aventis has the exclusive right to purchase the Unifill™ ready-to-fill syringe.

3 Mar 2010

Ichor, Profectus announce agreement for clinical development of DNA vaccine programs

Ichor Medical Systems (Ichor) and Profectus Biosciences (Profectus) announced today that they have entered into a long-term development, license, and supply Agreement providing Profectus with commercial access to Ichor’s TriGrid™ Delivery System (TriGrid™) for the clinical development of its DNA vaccine programs, with an option for Ichor to co-develop.

3 Mar 2010

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.

3 Mar 2010

Study shows cryoablation technique offers a potential treatment for breast cancer

Freezing a cancer kills it in its place, and also appears to generate an immune response that helps stop the cancer's spread, leading to improved survival rates over surgery, according to a new study in mice from researchers at the University of Michigan Comprehensive Cancer Center.

3 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

HTDS reports Gross Revenues of $5.39M for Fiscal Year ended December 31, 2009

Hard to Treat Diseases (http://www.htdsmedical.com) and its China based subsidiary Mellow Hope update shareholders on the company's 2009 revenues and profits.

2 Mar 2010

National Cancer Institute awards PDS Biotechnology $1.28M phase 2 SBIR contract

PDS Biotechnology Corporation today announced that the company has been awarded a $1.28M phase 2 SBIR contract by the National Cancer Institute division of the US National Institutes of Health. The contract provides funding to complete studies required to file an Investigational New Drug Application (IND) with the FDA for the company's lead human papillomavirus (HPV)-cancer product late in 2010.

2 Mar 2010

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

Sanquin Blood Supply Foundation, the Netherlands Cancer Institute, and the Netherlands Vaccine Institute announce today the launch of their joint AmpVacs project aiming at the development of a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats.

2 Mar 2010

California's dirty air costs more than $193M in hospital-based medical care, finds RAND study

California's dirty air caused more than $193 million in hospital-based medical care from 2005 to 2007 as people sought help for problems such as asthma and pneumonia that are triggered by elevated pollution levels, according to a new RAND Corporation study.

2 Mar 2010

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

The Greffex Group of regenerative medicine companies announces the signing of a Strategic Alliance Framework Agreement with UPMC and ISMETT, Italy.

2 Mar 2010

Stress increases resistance to influenza infection

A new study using mice suggests that a repeated stressful situation that triggers the animals' natural "fight-or-flight" response may actually enhance their ability to fight disease when re-exposed to the same pathogen.

2 Mar 2010

Intercell AG's revenues for full year 2009 increase 10.6%

Today, the biotech-vaccine company Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.

2 Mar 2010

Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its affiliate VGX International Inc. has received approval in Korea to begin a Phase I clinical trial in healthy volunteers for Inovio’s SynCon™ preventive DNA vaccine (VGX-3400) targeting H5N1 avian influenza.

2 Mar 2010

Archimedes Pharma raises GBP65 million in new funding

Archimedes Pharma, the leading specialty pharma company, today announced that it has raised GBP65 million (approx US$100 million) in new funding. The round was led by new investor Novo Growth Equity, the growth equity fund of Novo A/S, and included participation by major current investor, Warburg Pincus, a global private equity firm. Archimedes also announced the appointment of a new President and Chief Executive Officer, Jeffrey H. Buchalter, formerly President and Chief Executive Officer of US-based Enzon.

2 Mar 2010

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced the receipt of two US patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,632,059, covers methods for manufacturing recombinant antibodies.

2 Mar 2010

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

Researchers at the University of Nebraska Medical Center have taken a significant step forward in developing a vaccination approach to reverse the neurological damage seen with Parkinson's disease.

2 Mar 2010

McGill University and RI MUHC secure $300,000 CIHR grant to develop VLP vaccines

The Canadian Institutes of Health Research (CIHR) have awarded a $300,000 grant for research focusing on the nature of the immune response induced by the action mechanisms of plant-made Virus-Like Particles (VLP) to Dr. Louis Vezina, Chief Scientific Officer of Medicago and to Dr. Brian Ward and Dr. Ciriaco Piccirillo of the Research Institute of the McGill University Health Centre (RI MUHC) and McGill University.

1 Mar 2010

Breastfeeding and better hygiene may protect against peptic ulcer bacterium infection

Young children in developing countries are infected at an early age with the bacterium Helicobacter pylori, which can cause peptic ulcers and stomach cancer. New findings show that childrens´ immune responses help in fighting the bacteria. In addition, breastfeeding and better hygiene appear to protect against infection. The results provide hope for a vaccine, according to research from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

1 Mar 2010

Vaccine News and Research

Latest Vaccine News and Research

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

FDA issues final guidance to help develop safe and effective cell-based viral vaccines

Unilife agrees to Exclusivity List; Sanofi-aventis secures exclusivity for Unifill syringe

Ichor, Profectus announce agreement for clinical development of DNA vaccine programs

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Study shows cryoablation technique offers a potential treatment for breast cancer

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

HTDS reports Gross Revenues of $5.39M for Fiscal Year ended December 31, 2009

National Cancer Institute awards PDS Biotechnology $1.28M phase 2 SBIR contract

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

California's dirty air costs more than $193M in hospital-based medical care, finds RAND study

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

Stress increases resistance to influenza infection

Intercell AG's revenues for full year 2009 increase 10.6%

Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial

Archimedes Pharma raises GBP65 million in new funding

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

McGill University and RI MUHC secure $300,000 CIHR grant to develop VLP vaccines

Breastfeeding and better hygiene may protect against peptic ulcer bacterium infection

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in